Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 291

Sort by

Sort Order Select

Journal Articles

Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways

Denis F. Noubouossie, Michael W. Henderson, Micah Mooberry, Anton Ilich, Patrick Ellsworth, Mark Piegore, Sarah C. Skinner, Rafal Pawlinski, Ian Welsby, Thomas Renné, Maureane Hoffman, Dougald M. Monroe, Nigel S. Key

Blood (2020) 135 (10): 755–765.

https://doi.org/10.1182/blood.2019001643

Published: 2020

Includes: Supplemental data

Journal Articles

High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients

Blood (2019) 134 (Supplement_1): 1752.

https://doi.org/10.1182/blood-2019-128899

Published: 2019

Journal Articles

Characteristics and Financial Impact of Potentially Inappropriate Platelet Transfusion in the Inpatient Hospital Setting

Eric Mou, MD, Colin Murphy, MD, Jason Hom, MD, Lisa Shieh, MD, Neil Shah, MD

Blood (2019) 134 (Supplement_1): 2096.

https://doi.org/10.1182/blood-2019-125949

Published: 2019

Journal Articles

Patterns and Predictors of Emicizumab Adherence in People with Hemophilia

Ang Li, MD, Catlin Goodfriend, PharmD, John Sokol, PharmD, Rebecca Kruse-Jarres, MDMPH

Blood (2019) 134 (Supplement_1): 2178.

https://doi.org/10.1182/blood-2019-128083

Published: 2019

Journal Articles

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Patrick T. Ebbert, BS, Frederico Xavier, MD MS, Craig D. Seaman, MD MS, Margaret V. Ragni, MD MPH

Blood (2019) 134 (Supplement_1): 2416.

https://doi.org/10.1182/blood-2019-123198

Published: 2019

Journal Articles

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

Jing Deng, PhD, Tingting Mao, MS, Xiaojing Huang, PhD, Li Rui, Guangfeng Wang, PhD, Douglas D. Fang, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD

Blood (2019) 134 (Supplement_1): 2573.

https://doi.org/10.1182/blood-2019-128708

Published: 2019

Journal Articles

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Jill Reckless, Tom Knudsen, PhD DVM, Grant E. Blouse, PhD

Blood (2019) 134 (Supplement_1): 2420.

https://doi.org/10.1182/blood-2019-128971

Published: 2019

Journal Articles

Functional Interactions between Transcription Factors Involved in Myeloma Pathogenesis - Biological and Therapeutic Implications

Sondra L. Downey-Kopyscinski, PhD, Ricardo De Matos Simoes, PhD, Ryosuke Shirasaki, MD, Huihui Tang, PhD, Brian Glassner, PhD, Olga Dashevsky, PhD, Minasri Borah, Megan Bariteau, B.Sc., Richard Groen, John G Doench, PhD, Constantine S. Mitsiades, MD PhD

Blood (2019) 134 (Supplement_1): 315.

https://doi.org/10.1182/blood-2019-127502

Published: 2019

Journal Articles

Pathogenic Antibodies in Heparin-Induced Thrombocytopenia Specifically Target an Immunodominant Region on Platelet Factor 4

Angela Huynh, PhD, Donald M. Arnold, MD, John G. Kelton, MD, Rumi Clare, BSc, Marina Ivanova, Ishac Nazy, PhD

Blood (2019) 134 (Supplement_1): 219.

https://doi.org/10.1182/blood-2019-131462

Published: 2019

Journal Articles

In Vivo hemostatic Significance of Activated Protein C in Factor VIIIa Regulation

Amelia R. Wilhelm, B.S., Nicole A. Parsons, B.S., Charles T. Esmon, PhD, Rodney M. Camire, PhD, Lindsey A. George, MD

Blood (2019) 134 (Supplement_1): 93.

https://doi.org/10.1182/blood-2019-124493

Published: 2019

Journal Articles

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Blood (2019) 134 (Supplement_1): 3934.

https://doi.org/10.1182/blood-2019-124178

Published: 2019

Journal Articles

Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma

Larissa Haertle, PhD, Santiago Barrio, PhD, Michal Simicek, PhD, Umair Munawar, MSc, Ricardo Sanchez, PhD MD, Max Bittrich, MD, Matteo DaVia, MD, Cornelia Vogt, MSc, Nicola Giesen, MD, Andoni Garitano-Trojaola, PhD, Silvia Nerreter, Thorsten Stuehmer, PhD, Marc S. Raab, MD, Joaquin Martinez Lopez, MD PhD, Roman Hajek, MD, Hermann Einsele, MD, Leo Rasche, MD, Thomas Haaf, MD, Martin Kortüm, MD

Blood (2019) 134 (Supplement_1): 4349.

https://doi.org/10.1182/blood-2019-130847

Published: 2019

Journal Articles

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, G. David Roodman, MD PhD, Larry D. Cripe, MD, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Katie J Sargent, RN, Hamid Sayar, MD MSc, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2019) 134 (Supplement_1): 5051.

https://doi.org/10.1182/blood-2019-124384

Published: 2019

Journal Articles

Determining Postoperative Thrombocyte Reduction Cut Off to Predict 30-Day Mortality in Patients Undergo Coronary Artery Bypass Graft Surgery

Ikhwan Rinaldi, MD, Arif Mansjoer, MD

Blood (2019) 134 (Supplement_1): 4914.

https://doi.org/10.1182/blood-2019-125432

Published: 2019

Journal Articles

Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

Vibe Skov, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Thomas Stauffer Larsen, MD PhD, Torben A Kruse, Hans Hasselbalch, MD

Blood (2019) 134 (Supplement_1): 5396.

https://doi.org/10.1182/blood-2019-130560

Published: 2019

Journal Articles

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

Lei Guo, PhD, Jia Li, PhD, Hongxiang Zeng, PhD, Anna Guzman, Tingting Li, MD, Minjung Lee, MS, Yubin Zhou, PhD, Clifford Stephan, Peter J.A Davies, Margaret Goodell, PhD, Deqiang Sun, PhD, Mark A. Dawson, PhD MBBS, Yun Huang, PhD

Blood (2019) 134 (Supplement_1): 5053.

https://doi.org/10.1182/blood-2019-130586

Published: 2019

Journal Articles

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

Kensuke Kayamori, Cheng Zhong, Daisuke Shinoda, MD, Shuhei Koide, PhD, Motohiko Oshima, PhD, Yaeko Nakajima-Takagi, PhD, Naoya Mimura, MD PhD, Ryoji Ito, Kaoru Tohyama, MD PhD, William Lennox, Marla Weetall, PhD, Josephine Sheedy, BS, MSc, Emiko Sakaida, MD PhD, Koutaro Yokote, MD PhD, Atsushi Iwama, MD PhD

Blood (2019) 134 (Supplement_1): 5407.

https://doi.org/10.1182/blood-2019-125200

Published: 2019

Journal Articles

New Insights into Heme Utilization Pathways

Emanuela Tolosano, PhD

Blood (2019) 134 (Supplement_1): SCI-25.

https://doi.org/10.1182/blood-2019-121068

Published: 2019

Journal Articles

Plasma Kallikrein Contributes to Ellagic Acid-Induced Coagulation in the Absence of FXI By Activating Factor IX

Mayken Visser, Rene van Oerle, Hugo ten Cate, MD PhD, Volker Laux, PhD, Stefan Heitmeier, PhD, Henri M.H. Spronk, PhD

Blood (2019) 134 (Supplement_1): 1106.

https://doi.org/10.1182/blood-2019-131738

Published: 2019

Journal Articles

Autologous Stem Cell Transfusions on Multiple Days in Patients with Multiple Myeloma - Does It Matter?

Thomas Pabst, MD, Sebastian Moser, Ulrike Bacher, Barbara Jeker, Behrouz Mansouri Taleghani, Prof., Urban Novak

Blood (2019) 134 (Supplement_1): 3252.

https://doi.org/10.1182/blood-2019-127940

Published: 2019

NARROW

Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways

High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients

Characteristics and Financial Impact of Potentially Inappropriate Platelet Transfusion in the Inpatient Hospital Setting

Patterns and Predictors of Emicizumab Adherence in People with Hemophilia

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Functional Interactions between Transcription Factors Involved in Myeloma Pathogenesis - Biological and Therapeutic Implications

Pathogenic Antibodies in Heparin-Induced Thrombocytopenia Specifically Target an Immunodominant Region on Platelet Factor 4

In Vivo hemostatic Significance of Activated Protein C in Factor VIIIa Regulation

Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways

Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Determining Postoperative Thrombocyte Reduction Cut Off to Predict 30-Day Mortality in Patients Undergo Coronary Artery Bypass Graft Surgery

Highly Deregulated Fibulins in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes

New Insights into Heme Utilization Pathways

Plasma Kallikrein Contributes to Ellagic Acid-Induced Coagulation in the Absence of FXI By Activating Factor IX

Autologous Stem Cell Transfusions on Multiple Days in Patients with Multiple Myeloma - Does It Matter?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only